#RikenVitaminCoLtd

Between March 1 and March 23, 2026, 53,300 shares of treasury stock were acquired for a total of 156,067,693 yen, bringing the cumulative acquisition total to 696,500 shares with a total acquisition cost of 1,999,887,013 yen, and the acquisition has been completed.

Acquired 57,300 shares with a purchase price of 179,067,993 yen between February 1 and February 28, 2026. Total cumulative shares repurchased amount to 643,200 shares, with an aggregate purchase price of 1,843,819,320 yen.

For the third quarter of FY2026, consolidated net sales were 72,503 million yen (down 0.5% YoY), operating income was 5,716 million yen (down 24.2% YoY), and net income attributable to owners of the parent was 5,949 million yen (up 2.0% YoY).

Riken Vitamin Co., Ltd. announced a revision to its consolidated earnings guidance for the fiscal year ending March 2026, adjusting net sales to 96,000 million yen (down 4.0% from previous forecast), operating income to 6,200 million yen (down 27.1%), and net income attributable to owners of parent to 6,500 million yen (down 20.7%).

For Q3 FY2025, consolidated net sales were JPY 72,503 million (YoY -0.5%), operating income was JPY 5,716 million (YoY -24.2%), and net income was JPY 5,949 million (YoY +2.0%).

Acquired 62,200 shares of treasury stock totaling 190,219,693 yen from January 1 to January 31, 2026. The cumulative number of shares acquired is 585,900, with a total acquisition cost of 1,664,751,327 yen.